Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum-tolerated dose of ProMACE-CytaBOM

L. I. Gordon, J. Anderson, T. M. Habermann, J. N. Winter, J. Glick, R. J. Schilder, P. Cassileth

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum-tolerated dose of ProMACE-CytaBOM'. Together they form a unique fingerprint.

Medicine & Life Sciences